Join an executive panel exploring innovations in sterile filling for drug-device delivery, strategic collaborations, and CDMO value redefined to meet evolving market needs. Gain insights into advancing biologic administration from trials to commercial scale. Register now!

The U.S. Most Favored Nation (MFN) policy is moving from debate to enforcement with 60-day deadlines, affecting launch pricing, contracts, and global sequencing. Explore key policy insights and impacts in Herspiegel’s Policy Brief.

Discover how the vaginal microbiome impacts women’s health and how the OMNIgene™•VAGINAL kit empowers reliable, easy self-collection and preserves high-quality microbial DNA/RNA for up to 30 days. Download the white paper to explore its role in advancing women’s health research.

Oncology licensing deals are moving faster than ever, with shrinking windows and rising competition. This infographic outlines four strategies sponsors can use to accelerate readiness, boost asset value, and secure stronger deals.

Efficient language solutions can make or break clinical trials by impacting cost, timelines, and patient engagement. Download this white paper to explore best practices and strategies for reducing risk and accelerating R&D.

Transitioning from clinical stage to commercial is just the start. This paper explores how cell & gene supply chains must always evolve as a company matures.

Middlesex County, NJ is becoming a leading hub for biotech and drug development, offering talent, resources, and infrastructure to help life science companies thrive. Download the free report today to see why it’s the smart choice for your next stage of growth.